sacrosidase


Also found in: Wikipedia.

sacrosidase

 [sak-ro´sĭ-dās]
an enzyme used as a substitute to replace the sucrase activity lacking in sucrase-isomaltase deficiency, administered orally.
References in periodicals archive ?
Global Banking News-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
Biopharmaceutical company QOL Medical LLC revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) to manufacture Sucraid (sacrosidase) Oral Solution for the treatment of congenital Sucrase-Isomaltase Deficiency at its wholly owned manufacturing facility in Clearwater, Florida.
The company has developed an improved manufacturing process for sacrosidase production, designed and built a wholly owned cGMP-compliant manufacturing facility, and hired an experienced manufacturing and quality team to assure this goal.
M2 EQUITYBITES-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
M2 PHARMA-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
The FDA has issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.
Consider this diagnosis, especially in children, and treat it with sacrosidase, Dr.
The increase results from pre tax gains associated with the previously announced divestments of Busulfex(R) (busulfan) Injection and Sucraid (R)(sacrosidase) oral solution.